Meibairui, a subsidiary of Rongchang biology, creates the largest cro and CMO company in Asia

          Recently, the official website of the Ministry of science and technology of the people's Republic of China announced "a new class I drug independently developed by Yantai Rongchang Pharmaceutical Co., Ltd and Yantai Rongchang Bioengineering Co., Ltd for the treatment of various cancers such as gastric cancer, ovarian cancer, breast cancer and non-small cell lung cancer with overexpression of HER2" (rc48), a recombinant human anti HER2 monoclonal antibody MMAE coupling agent for injection "(rc48), which has completed preclinical research and core technology In November 2013, the application for national invention patent was filed, and the clinical experiment application was accepted on August 26, 2014 On September 24, 2014, the State Administration of food and Drug Administration of the people's Republic of China issued a letter to the State Administration of food and drug to evaluate the drug as the first breast cancer ADC antibody drug to be applied for clinical application, with good innovation Yantai Rongchang Bioengineering Co., Ltd is ushering in a gorgeous butterfly transformation In addition to rc48, the company has 7 national first-class new drugs under development, one of which is in phase II clinical research, and three new drugs are about to apply for clinical research Together with Tongji University and Yida company of the Development Zone, the company has also established the largest new biological medicine R & D, production and OEM in Asia For many years, people have been talking about cancer discoloration With the birth of rc48, cancer patients see new hope "Drugs that treat cancer are not only expensive, they don't have a high cure rate." Fang Jianmin, general manager and chief scientist of Yantai Rongchang Bioengineering Co., Ltd., said, "thinking of these, we decided to focus on tumor antibody drugs." Fang Jianmin studied in Canada and the United States and has been engaged in new drug research for nearly 20 years Knowing that there is a huge gap in cancer diagnosis and treatment between China and the United States, he resolutely gave up the preferential treatment given by the United States In 2008, he married Yantai Rongchang Pharmaceutical Co., Ltd to establish Yantai Rongchang Bioengineering Co., Ltd and a group of researchers from the United States came to study antibody drugs for 7 years With this enthusiasm, Rongchang biology has developed 7 national first-class new drugs at one go Fang Jianmin said that the company's products under research are internationally leading Among them, "rc-18" (tai'ai), a new biological drug, is a kind of biotechnology drug for the treatment of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis It has obtained the invention patent authorization from China, the United States and Russia At present, it is in the phase II clinical research stage, and it is a key special support project for the national "11th Five Year" and "12th Five Year" new drug creation At the same time, we also developed rc-28, rc-38, rc-48, rc-58, rc-68, pc-88 and other biological drugs with independent intellectual property rights "By 2016, three to four new drugs will be declared for clinical application." Fang Jianmin said New drug research and development has received more support When it comes to these, Huang Changjiang, deputy general manager of Yantai Rongchang Bioengineering Co., Ltd., is a treasure "Tai'ai" has received more than 6 million National Science and technology project funds; rc48, RC58, rc68 three new drugs are major special projects, which have received more than 24 million yuan of national science and technology project funds; at the end of 2014, the national, provincial, municipal and district four levels determined to support more than 100 million yuan of scientific research funds Five high-end talents create the largest cro and CMO company in Asia If you want to improve the domestic biomedical market, you need to extend the biomedical industry chain At this point, China's development is more than a little slower than that of the United States In 2013, Yantai Mai Bairui international biomedical Co., Ltd was established, becoming the largest biomedical cro and CMO company in Asia, providing new drug R & D and production OEM services for customers at home and abroad "Maberry has the ability of" one-stop "new drug development and production from gene cloning, cell bank establishment, medium development and large-scale production, drug coupling, small-scale test expression, new drug registration design, clinical experimental reagents, pilot scale-up to GMP large-scale production Its service range runs through the whole process from drug discovery to market." "Biomedical enterprises at home and abroad only need to place an order, and the rest of the huge projects will be completed by mabri," said Ruan Maorong, vice president of Yantai mabri international biomedical Co., Ltd Advanced R & D technology comes from a strong R & D team The R & D team of the company has more than 10 doctors and 40 masters, and has introduced 5 overseas innovative talents successively Among them, two were identified as national "thousand talents plan" special experts; three were identified as "Taishan Scholars" special experts in Shandong Province At present, more than 80% of the company's employees have bachelor's degree or above Among them, more than 40% have doctorates and master's degrees.